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Nanometer size particles are small 

































– Product lifecycle management
7
Current practices are process intensive 
and harsh for fragile API.
Shear Polymorphism




For example, the bioavailability of 
poorly soluble drugs can be enhanced. 
Spironalactone is a synthetic 17-lactone steroid.  Nanoparticle 
suspensions of this drug dramatically enhance the drug dissolution.
9
For example, tumor accumulation via 
“enhanced permeability and retention.”
10
For example, tumor accumulation via 




How do you create particles?
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www.buchi.com and LaVan, et al. (2002)
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Wet milling provides a method to reduce 
the particle size of poorly soluble API.
www.elan.com and Merisko-Liversidge, et al. (2003)
Intensive process         
Particle recovery required
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Air jet milling reduces particle size to 1-
30 microns or smaller. 
Air jet milling
– Particle-particle collisions 
– No heat or moving parts




Spray drying can be utilized for 










Particle diameter ~3 microns
leads to deep lung deposition





For background see Rabinow (2004)
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Crystals can be designed to be small 
and friable for nanosizing.
www.baxterbiopharmsolutions.com
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Crystal formation at higher T
www.accentus.com
21
Nucleation induced by sonication 
increases crystal homogeneity and yield.
Sonication techniques applied to emulsion crystalization processes 




decreases particle size (submicron).
Rabinow (2004)
23






For a review, see Yeo, et al. (2005)
26
Ultrasonic nozzle, SCF anti-solvent 
(SAS) process offers decent scalability. 
Maximum Capacity:  0.5 kg/8 h www.crititech.com
27
SCFs provide high diffusion coefficients 
for rapid/complete solvent extraction. 
Reduced particle size by SAS
Narrow size distributions
Small molecules, proteins and peptides
Minimal residual solvent
www.crititech.com
Before processing After processing
Expensive?
28
Spray-freezing into SCF provides a 
novel means to create protein particles.
Williams, et al. (2004), Leach, et al. (2005) and www.alkermes.com
Spray-freezing into SCF produces 
micron or sub-micron protein 
particles.  Particles can also be 
homogenized in SCF (cryo-milled) to 







Baxter’s PROMAXX microspheres have 
decent size control for API delivery. 
Sustained or immediate release
Sized for delivery









Pure protein particles produced by 
freeze-drying with PEG, removing PEG.
Freeze-drying albumin with PEG particles.





Morita, et al. (2000)
32
Bulk “gel” materials can be made from 







Dendrimers are gaining interest for 
delivering drugs and sensing.
Easy formulation?
Size control (Mw)
Complex or intercolate drugs




Polyelectrolyte complexes can be 
formulated to contain API.
Long used for gene delivery, PEI-DNA
Recently, for enhanced transport across BBB
Ogawa (2005), Li (2004) and Vinogradov (2004)
Drug is usually mixed 
with polymer 1 (binding) 
and polymer 2 
(opposite charge) is 
dripped in with mixing 
to form nanogels via 
ionic complexation. 
36
LBL-Technology® can form capsules by 
using uniform particle templates.
Ger. Offen.  (2004) and Peyratout (2004)
Ordered shells
Dense shells
4-24+ layers (8-50 nm)          
API encapsulation
– Entrapped in layer
– Partitioned into core          
Surface active
37
LBL controls drug locale, particle 
morphology or coating of drug crystals.
Ger. Offen.  (2004) and Peyratout (2004)
API crystals can be 
selectively coated
Drug localized to specific 
shell layer or core.






Block copolymers self assemble in 
solution to form micelles.
Nishiyama (2006)
40
Block copolymers entrap poorly soluble 
drugs in the core of micelles.
Improved solubility of poorly 
soluble drug
Amprenavair – HIV protease 
inhibitor 
Formulated with Vitamin E 




~40 nm diameter 
41
Micelles accumulate in tumors through 
“enhanced permeability and retention.”





Liposomes like the STEALTH® liposome 
may target delivery.
PEG coating
– Reduces MPS uptake 
– Increase residence
– Plasma stability 
Lipid shell/water core
– Decent drug load





Been around and minimal products
www.alza.com
44
Polymersomes offer an attractive 
alternative to liposomal formulations.




Worms circulate 1 week!
45
Combination chemotherapy reduced 
tumor size in vivo.
Polymersomes loaded with 
paclitaxel and doxorubicin
improve the performance of these 
drugs by accumulating in the 
tumor after IV injection and 






47 Vicent (2004), Nishiyama (2006)
48
Berkland
Lab Dry powder aerosols
– Cystic Fibrosis Foundation, PhRMA Foundation
Protein stabilization in nanoparticles
– American Heart Association
Nanoparticle targeting
– Juvenile Diabetes Research Foundation
Intracellular drug delivery
– NIH, HBC, KMCRI
Implantable controlled release films
– Juvenile Diabetes Research Foundation
49



























- Product lifecycle management
50
Micro- and nanoparticles possess 
advantages for discrete applications.
Microparticles
- Control release rate






Depots - ~10-100 µm
Nasal - ~10 µm
Lung - ~2-10 µm
- Immune response
Vaccine adjuvant ~1-5 µm
Nanoparticles
- Enhance dissolution 
Poorly water soluble 
drugs
- Extend circulation
>10 nm retained in blood
- Passive targeting
Enhanced permeability 
and retention (tumors) 
~100 nm
- Enter cells
Intracellular drug delivery 
<200 nm
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~100 nm silica 
nanoparticles
52
Ciprofloxacin nanoparticles associated 














Exercising control over micro- and
nanoparticle structure.
Nanoparticles as building blocks pH-sensitive nanoparticle clusters
54
Coating nanoparticles with PNVF 
allowed dispersion in response to pH. 
Nanoparticle clusters disperse over a few 







Controlled agglomeration of 



































Self assembled PLGA nanoparticles 





(+)  PLGA particles
Scale bar = 10 µm
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pH sensitive nanocapsules may 
selectively deliver drugs intracellularly.































May need to match 
method to particular 
API formulation.





Conners, et al. (2004)
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